Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
The Dual Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) Antagonist, Sparsentan, Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy
The Dual Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) Antagonist, Sparsentan, Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy
The Dual Endothelin/Angiotensin II Receptor (ETAR/AT1R) Antagonist Sparsentan Slows Renal Disease, Improves Lifespan, and Attenuates Hearing Loss in Alport Mice: Comparison with Losartan and Atrasentan
The Dual Endothelin/Angiotensin II Receptor (ETAR/AT1R) Antagonist Sparsentan Slows Renal Disease, Improves Lifespan, and Attenuates Hearing Loss in Alport Mice: Comparison with Losartan and Atrasentan
No Impact of Newly Initiated Immunosuppressive Therapy Observed on Long-Term Antiproteinuric Effect of Sparsentan in Focal Segmental Glomerulosclerosis: Interim 84-Week Analysis of the DUET Trial